睾酮治疗与癌症风险。

Testosterone therapy and cancer risk.

机构信息

Department of Urology, Stanford University School of Medicine, Stanford, CA, USA; Department of Obstetrics/Gynecology, Stanford University School of Medicine, Stanford, CA, USA.

出版信息

BJU Int. 2015 Feb;115(2):317-21. doi: 10.1111/bju.12756. Epub 2014 Oct 20.

DOI:10.1111/bju.12756

PMID:24684569

Abstract

OBJECTIVE

To determine if testosterone therapy (TT) status modifies a man's risk of cancer.

PATIENTS AND METHODS

The Urology clinic hormone database was queried for all men with a serum testosterone level and charts examined to determine TT status. Patient records were linked to the Texas Cancer Registry to determine the incidence of cancer. Men accrued time at risk from the date of initiating TT or the first office visit for men not on TT. Standardised incidence rates and time to event analysis were performed.

RESULTS

In all, 247 men were on TT and 211 did not use testosterone. In all, 47 men developed cancer, 27 (12.8%) were not on TT and 20 (8.1%) on TT. There was no significant difference in the risk of cancer incidence based on TT (hazard ratio [HR] 1.0, 95% confidence interval [CI] 0.57-1.9; P = 1.8). There was no difference in prostate cancer risk based on TT status (HR 1.2, 95% CI 0.54-2.50).

CONCLUSION

There was no change in cancer risk overall, or prostate cancer risk specifically, for men aged >40 years using long-term TT.

摘要

目的

确定睾丸激素治疗（TT）是否会改变男性患癌的风险。

方法

查询泌尿科激素数据库中所有具有血清睾丸激素水平的男性，并检查图表以确定 TT 状态。将患者记录与德克萨斯癌症登记处相关联，以确定癌症的发病率。对于开始 TT 或未使用 TT 的男性首次就诊时，男性将按风险时间累积。进行标准化发病率和事件时间分析。

结果

共有 247 名男性接受 TT 治疗，211 名男性未使用睾丸激素。共有 47 名男性患癌症，27 名（12.8%）未接受 TT 治疗，20 名（8.1%）接受 TT 治疗。根据 TT，癌症发病率的风险没有显著差异（风险比 [HR] 1.0，95%置信区间 [CI] 0.57-1.9；P = 1.8）。根据 TT 状态，前列腺癌风险没有差异（HR 1.2，95% CI 0.54-2.50）。